04
2020-08
Results of Kintor's Phase Ib Clinical Trials of Pyrilutamide in America
Kintor Pharmaceutical Limited (stock code: 9939.HK, hereinafter referred to as "Kintor" or the "Company") announced that the phase Ib clinical trials of Pyrilutamide (KX-826) against androgenetic alopecia were completed in the United States. All subjects exited the trials. Data analysis, cleaning and summarisation are underway.
30
2020-07
Kintor Pharmaceutical Limited (“Kintor Pharmaceutical” or the “Company”, stock code 9939.HK) announced that the Company has entered a partnership agreement with Alphamab Oncology (stock code: 9966.HK), to jointly develop the combination therapy of ALK-1 monoclonal antibody GT90001 and PD-L1 / CTLA-4 bispecific antibody KN046 in hepatocellular carcinoma (HCC).
19
2020-07
Kintor Pharmaceutical Limited (“Kintor Pharmaceutical” or the “Company”, stock code 9939.HK) announced the completion of patients enrolment according to the clinical protocol for phase II clinical trials (NCT03899467) of Proxalutamide (GT0918) in the United States for treating metastatic castration-resistant prostate cancer (“mCRPC”).
14
2020-07
Kintor to Colloborate with Applied Biology in COVID-19 Study of Proxalutamide
Jiangsu, China, July 12, 2020 - Suzhou Kintor Pharmaceutical, Inc. a wholly-owned subsidiary of Kintor Pharmaceutical Limited (“Kintor Pharma”, 9939.HK), and Applied Biology, Inc. entered into a clinical trial research agreement ("Research Agreement"), pursuant to which Suzhou Kintor collaborates with Applied Biology to conduct research for Proxalutamide (GT0918) as a treatment for the novel coronavirus disease ("COVID-19"). We believe that this study is an innovative attempt to use anti-androgens as a possible treatment to devastating COVID-19 worldwide pandemic .
28
2020-06
Kintor Pharmaceutical Signs Strategic Cooperation Agreement with JD Pharmacy
Kintor Pharmaceutical Limited announced that it has signed a strategic cooperation framework agreement with JD Pharmacy, the pharmaceutical retail channel under JD Health, in a concerted effort to create a patient-centred online innovative healthcare ecosystem. JD Pharmacy will utilise its abundant traffic and resources and strong technological and supply chain capabilities to assist Kintor Pharmaceutical in the marketing and sales of the innovative External use drug KX-826.
22
2020-05
Kintor Pharmaceutical successfully listed on HKEX today
Kintor Pharmaceutical Limited (Stock Code:9939.HK) has successfully been listed on the Main Board of the Stock Exchange of Hong Kong Limited on 22,May 2020.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn